$0.87 +0.03 (3.82%) OncoGenex Pharmaceuticals Inc - NASDAQ

Jul. 26, 2016 | 03:59 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 0.87
Trade Time: Jul 26 03:59 PM Eastern Daylight Time
Change: +0.03 (3.82%)
Prev Close: 0.84
Open: 0.84
Bid: 0.87
Ask: 0.88
  1. No results found.
  1. OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

    Benzinga | Jan. 20, 2016 | 16:02PM EST
  2. OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial

    Benzinga | Dec. 9, 2015 | 07:01AM EST
  3. Benzinga's Top Downgrades

    Benzinga | Dec. 2, 2015 | 09:31AM EST
  4. OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment

    Benzinga | Oct. 8, 2015 | 07:00AM EST
  5. OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

    Benzinga | Sep. 30, 2015 | 07:03AM EST
  6. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 28, 2015 | 08:14AM EST
  7. OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes

    Benzinga | Sep. 28, 2015 | 04:05AM EST
  8. US Stock Futures Rise Ahead Of Manufacturing PMI

    Benzinga | Sep. 23, 2015 | 07:52AM EST
  9. OncoGenex Pharma Offers Phase 2 Rainier Results Related to Previously Untreated Metastatic Pancreatic Cancer

    Benzinga | Sep. 23, 2015 | 07:02AM EST
  10. An Update On Phase 3 ENSPIRIT Trial - Report on OncoGenex Pharmaceuticals

    Benzinga | Aug. 4, 2015 | 09:22AM EST
  11. US Stock Futures Signal Higher Start On Wall Street

    Benzinga | Jul. 13, 2015 | 07:16AM EST
  12. OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis

    Benzinga | Jul. 13, 2015 | 07:01AM EST
  13. FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment

    Benzinga | Jun. 10, 2015 | 07:00AM EST
  14. US Stock Futures Slip Ahead Of Home Price, Consumer Confidence Data

    Benzinga | Dec. 30, 2014 | 07:10AM EST
  15. OncoGenex to Regain Rights to Custirsen from Teva

    Benzinga | Dec. 30, 2014 | 07:03AM EST
Trading Center